Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats

Drug Metabolism and Disposition

Volumn 25, Issue 3, 1997, Pages 362-366

  Shaw, Jeng Pyng ^a   Louie, Michael S ^b   Krishnamurthy, V V ^b   Arimilli, Murty N ^b   Jones, Robert J ^b   Bidgood, Alison M ^b   Lee, William A ^b   Cundy, Kenneth C ^b  

^a GILEAD SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG BINDING; DRUG METABOLISM; DRUG SELECTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOPHILICITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PHOSPHONIC ACIDS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 0030997246     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. J. Balzarini, L. Naesens, P. Herdewijn, I. Rosenberg, A. Holy, R. Pauwels, M. Baba, D. G. Johns and E. De Clercq: Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc. Nat. Acad. Sci. U.S.A. 86, 332-336 (1989).
2. R. E. Walker, S. E. Vogel, H. S. Jaffe, M. A. Pollis, J. A. Kovacs, J. Falloon, R. T. Davey, D. Ebeling, K. C. Cundy, D. Paar, N. Markowitz, H. Masur and H. C. Lane. A phase I/II study of PMEA in HIV infected patients. In "First National Conference on Human Retroviruses," Washington, D.C. (Abstract), p. 522, 1994.
3. J. E. Starrett, M. M. Mansuri, J. C. Martin, D. R. Tortolani and J. J. Bronson. European Patent 481, 214, A1. April 1992.
4. K. C. Cundy, J.-P. Shaw, and W. A. Lee: Oral, subcutaneous and intramuscular bioavailability of the antiviral nucleotide analog 9-(2-phosphonylmethoxy-ethyl)adenine (PMEA) in cynomolgus monkeys. Antimicrob. Agents Chemother. 38, 365-368 (1994).
5. K. C. Cundy, P. Barditch-Crovo, R. E. Walker, A. C. Collier, D. Ebeling, J. Toole, and H. S. Jaffe. Clinical pharmacokinetics of Adefovir in Human Immunodeficiency Virus Type 1-infected patients. Antimicrob. Agents Chemother. 39, 2401-2405 (1995).
6. G. Palu, S. Stefanelli, M. Rassu, C. Parolin, J. Balzarini, and E. De Clercq: Cellular Uptake of Phosphonylmethoxyalkylpurine Derivatives. Antiviral Res. 16, 115-119 (1991).
7. J. E. Starrett, D. R. Tortolani, M. J. M. Hitchcock, J. C. Martin, and M. M. Mansuri: Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl)-9-(2-phosphony!-methoxyethyl)adenine. Antiviral Res. 19, 267-273 (1992).
8. J.-P. Shaw and K. C. Cundy: Biological screens of PMEA prodrugs. Pharm Res. 10, (Suppl.), S294 (1993).
9. K. C. Cundy, J. A. Fishback, J.-P. Shaw, M. L. Lee, K. F. Soike, G. C. Visor, and W. A. Lee: Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxy-ethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm. Res. 11, 839-843 (1994).
10. P. A. Barditch-Crovo, K. C. Cundy, M. Wachsman, J. Toole, H. Burgee, D. Ebeling et al. Pharmacokinetic profile of 9-[2-(bis-pivaloyloxymethyl) phosphonylmethoxyethyl]adenine (bis-POM PMEA), an orally bioavailable prodrug of the antiviral nucleotide, PMEA. In "The Second National Conference on Human Retroviruses," Washington, D.C. (Abstract), p. 488, 1995.
11. J.-P. Shaw, R. J. Jones, M. A. Arimilli, M. S. Louie, W. A. Lee, and K. C. Cundy: Oral bioavailability of PMEA from PMEA prodrugs in male Sprague-Dawley rats. Pharm. Res. 10, (Suppl.) S402 (1994).
12. T. Mukaiyama and M. Hashimoto. Synthesis of oligothymidylates and nucleoside cyclic phosphates by oxidation-reduction condensation. J. Am. Chem. Soc. 94, 8528-8532 (1972).
13. J. W. Russell, D. Marrero, V. J. Whiterock, L. J. Klunk, and J. E. Starrett: Determination of 9-[(2-phosphonylmethoxy)-ethyl]adenine in rat urine by High-Performance Liquid Chromatography with fluorescence detection. J. Chromatogr. (Netherlands) 572, 321-326 (1991).
14. R. E. Notari: Pharmacokinetic aspects of prodrug design and evaluation. In "Design of Prodrugs" (H. Bundgaard, ed.), pp. 135-156. Elsevier, New York, 1985.
15. K. Kondo, H. Iwasaki, N. Ueda, K. Takemoto, and M. Imoto: Vinyl Compounds of Nucleic Acid Bases. II Synthesis and Polymerization of N-β-Methacryloyloxyethyl Derivatives of Uracil, Thymine, Theophylline, 2-Chloro-6-methylpurine, and Adenine. Die Macromolar Chemie 120, 21-26 (1968).
16. Bristol-Myers. Determination of oral bioavailability of BMY 40085, 9-(2-phosphonylmethoxyethyl)adenine (PMEA) when administered as prodrugs to the rat. Study No. WHIT-VJ-25804. Bristol-Myers, Wallingford, CT (1991).
17. A. S. Jones, P. Lewis, and S. F. Withers: The synthesis of carboxymethyl derivatives of purines and pyrimidines. Tetrahedron 29, 2293-2298 (1973).